Myocardial Infarction News and Research

RSS

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

19 Oct 2009

ESC comments on France preparing to authorise the sale of cigarettes on the internet

The European Society of Cardiology wishes to comment on media reports this week that France is preparing to authorise the sale of cigarettes on the internet, to conform to European rights.

19 Oct 2009

Elected officials have no excuse for failing to enact comprehensive smoke-free workplace laws: IOM

A landmark report released today by the Institute of Medicine provides powerful new evidence that elected officials have no excuse for failing to enact comprehensive smoke-free workplace laws. The IOM report concludes smoke-free laws reduce the number of heart attacks and save lives. The report also confirms that there is conclusive scientific evidence that secondhand smoke causes heart disease, including heart attacks, and finds there is compelling evidence that even relatively brief exposure to secondhand smoke can lead to a heart attack.

19 Oct 2009

Study reveals the cost effectiveness of Rheos blood pressure lowering device

A study conducted by the University of Rochester Medical Center demonstrates that, for certain patient populations, an experimental device that lowers blood pressure may be a cost effective treatment. The implantable device, called Rheos, is in advanced stages of testing for individuals with drug resistant hypertension.

19 Oct 2009

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that the European Patent Office intends to grant two key patents related to the Company's intellectual property on its two pharmaceutical candidates Annexin A5 and PC-mAb.

14 Oct 2009

Cambridge Heart to showcase Microvolt T-Wave Alternans technology at 2009 Annual Meeting Conference

Cambridge Heart, Inc. (OTCBB-CAMH) will participate in the Sudden Cardiac Arrest Association’s 2nd Annual Meeting and Medical Education Conference in Chicago, Illinois October 9th through the 11th, to showcase their Microvolt T-Wave AlternansTM (MTWA) technology designed to identify patients at risk for Sudden Cardiac Arrest (SCA).

9 Oct 2009

Clinical and health status outcomes information repository of heart attack patients completed

An important observational registry evaluating processes of care and one-year outcomes of over 4300 heart attack patients is now being completed. Researchers at the Saint Luke's Mid America Heart Institute in Kansas City, MO have led this observational research study in collaboration with 23 other hospitals throughout the U.S.

8 Oct 2009

Award-winning GWTG hospitals have lower mortality rates for heart attack and heart failure patients: Study

Hospitals receiving performance awards from the American Heart Association's Get With The Guidelines (GWTG) quality improvement initiative have lower mortality rates for heart attack and heart failure patients than all other hospitals, according to a new study.

7 Oct 2009

Myocardial and neurological effects of Tβ4 presented

REGENERX BIOPHARMACEUTICALS, INC. today reported on the results of several important research programs with Thymosin beta 4 (Tβ4) presented at the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy.

5 Oct 2009

Genentech announces two Phase III study results of Lucentis

Genentech, Inc., a wholly-owned member of the Roche Group, today announced results from two Phase III studies of Lucentis (ranibizumab injection) in macular edema due to retinal vein occlusion (RVO), which showed, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections.

5 Oct 2009

70% of Americans underestimate the seriousness of SCA

More than 250,000 deaths occur each year as a result of sudden cardiac arrest (SCA). In fact, SCA claims one life every two minutes, taking more lives each year than breast cancer, lung cancer or AIDS. Yet, according to a recent survey issued by the Heart Rhythm Society, more than 70 percent of Americans not only underestimate the seriousness of SCA, but also believe SCA is a type of heart attack.

3 Oct 2009

Clinical study data of Thymosin beta 4 presented

REGENERX BIOPHARMACEUTICALS, INC. today reported on several clinical studies with Thymosin beta 4 (Tβ4) presented the Second International Symposium on Thymosins in Health and Disease, in Catania, Italy.

3 Oct 2009

Stem cell therapy aims to prevent permanent damage from heart attacks

All patients arriving at UCSF's Emergency Department with heart attack will continue to be treated with standard measures. Patients who meet the medical criteria for the trial will be able to elect to receive the stem cell therapy within seven days after their heart attack.

1 Oct 2009

ACS NSQIP recognizes Baylor Dallas for achieving exemplary outcomes for surgical patient care

Baylor University Medical Center at Dallas has been recognized as one of 25 hospitals in the nation achieving exemplary outcomes for surgical patient care.

1 Oct 2009

Consumption of fish has no major role in protection against heart failure

The consumption of fish has no major role in the prevention of heart failure, according to results from a large prospective population study. The study, which was started in 1990 and involved all men and women over the age of 55 living in a suburb of Rotterdam, found no difference in the risk of developing heart failure between those who did eat fish and those who didn't.

1 Oct 2009

Houston Northwest Medical Center recognized as Cycle III Chest Pain Center with PCI

In its continuous pursuit of quality cardiac care, Houston Northwest Medical Center was proudly recognized as the first accredited chest pain center in Houston and one of a handful in Texas to be named a Cycle III Chest Pain Center with PCI (percutaneous coronary intervention).

30 Sep 2009

HORIZONS-AMI clinical trial demonstrates efficacy of drug-eluting stent

Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.

25 Sep 2009

Phase III PLATO study proves that ticagrelor is more effective than clopidogrel

New data from the phase III PLATO study showed that ticagrelor (BRILINTA((TM))) provided greater reduction of cardiovascular (CV) events (composite of CV death, heart attack and stroke) than clopidogrel (9.02% vs. 10.65%,>

25 Sep 2009

Athera Biotechnologies and ALPCO sign distribution agreement

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), and ALPCO, a company providing high quality research immunoassays, announced today that they have signed a distribution agreement.

25 Sep 2009

Everolimus-eluting stent efficient in treating native coronary artery lesions

Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.

24 Sep 2009

Myocardial Infarction News and Research

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

ESC comments on France preparing to authorise the sale of cigarettes on the internet

Elected officials have no excuse for failing to enact comprehensive smoke-free workplace laws: IOM

Study reveals the cost effectiveness of Rheos blood pressure lowering device

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

Cambridge Heart to showcase Microvolt T-Wave Alternans technology at 2009 Annual Meeting Conference

Clinical and health status outcomes information repository of heart attack patients completed

Award-winning GWTG hospitals have lower mortality rates for heart attack and heart failure patients: Study

Myocardial and neurological effects of Tβ4 presented

Genentech announces two Phase III study results of Lucentis

70% of Americans underestimate the seriousness of SCA

Clinical study data of Thymosin beta 4 presented

Stem cell therapy aims to prevent permanent damage from heart attacks

ACS NSQIP recognizes Baylor Dallas for achieving exemplary outcomes for surgical patient care

Consumption of fish has no major role in protection against heart failure

Houston Northwest Medical Center recognized as Cycle III Chest Pain Center with PCI

HORIZONS-AMI clinical trial demonstrates efficacy of drug-eluting stent

Phase III PLATO study proves that ticagrelor is more effective than clopidogrel

Athera Biotechnologies and ALPCO sign distribution agreement

Everolimus-eluting stent efficient in treating native coronary artery lesions

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News